The lung surfactant market is a specialized yet vital segment of the pharmaceutical industry, providing life-saving therapies for premature infants suffering from respiratory distress syndrome (RDS). The lung surfactant market is driven by the high prevalence of preterm births and the continuous need for effective respiratory support. The global market is projected to grow from an estimated USD 3.72 billion in 2025 to USD 6.49 billion by 2035, at a steady CAGR of 5.18%.

Lung surfactants are complex mixtures of phospholipids and proteins that reduce surface tension in the alveoli, preventing lung collapse and facilitating gas exchange. They are crucial for treating neonatal RDS, a condition that affects over 40,000 infants annually in the United States and Canada alone. The market is characterized by a mix of animal-derived and synthetic surfactants, with key products including poractant alfa, beractant, calfactant, and lucinactant.

Several factors are driving market growth. The increasing rate of preterm births and the rising prevalence of respiratory infections are primary drivers. Furthermore, technological advancements in surfactant formulations and drug delivery methods, along with growing investment in healthcare infrastructure, are expected to create new opportunities. For a comprehensive analysis of the key players, market segmentation, and regional trends, exploring the lung surfactant market is recommended.